# OnCo record paper-keynote-483-lancet-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-keynote-483-lancet-2023/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-keynote-483-lancet-2023" ;
  schema:name "KEYNOTE-483 (CCTG IND.227): pembrolizumab plus chemotherapy versus chemotherapy in untreated pleural mesothelioma"@en ;
  schema:description "Adding pembrolizumab to platinum-pemetrexed chemotherapy lengthened survival in untreated pleural mesothelioma by about a year in non-epithelioid tumours and by a smaller margin overall, giving a chemo-immunotherapy option alongside nivolumab-ipilimumab."@en ;
  schema:url <https://onco.cc/key-papers/paper-keynote-483-lancet-2023/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/S0140-6736(23)01613-6>, <https://pubmed.ncbi.nlm.nih.gov/37931632/> ;
  schema:sameAs <https://doi.org/10.1016/S0140-6736(23)01613-6> ;
  schema:datePublished "2023"^^xsd:gYear ;
  schema:author "Chu Q, Perrone F, Greillier L, et al." ;
  onco:cancers <https://onco.cc/cancers/pleural-mesothelioma/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:trials <https://onco.cc/trials/keynote-483/> ;
  onco:journals <https://onco.cc/journals/lancet/> .